Annual report pursuant to Section 13 and 15(d)

Note 12 - Segment Information (Tables)

Note 12 - Segment Information (Tables)

12 Months Ended

Jun. 30, 2015

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended June 30,
	2015			20 14		20 13
External sales
Biotechnology	$	325,897		$	300,578	$	288,156
Clinical Controls		60,377			57,185		22,419
Protein Platforms		66,247			0		0
Inter segment		(273	)		0		0
Consolidated net sales	$	452,246		$	357,763	$	310,575

	Year Ended June 30,
	2015			20 14			20 13
Operating Income
Biotechnology	$	171,059		$	168,041		$	164,886
Clinical Controls		18,148			17,556			8,746
Protein Platforms		4,469			0			0
Segment operating income		193,675			185,597			173,632
Costs recognized upon sale of acquired inventory		(6,958	)		(7,480	)		(4,501	)
Amortization of intangibles		(26,169	)		(10,276	)		(5,061	)
Acquisition related expenses		(4,519	)		(2,247	)		(607	)
Corporate general, selling and administrative expenses		(9,007	)		(5,845	)		(4,994	)
Consolidated operating income	$	147,022		$	159,750		$	158,469

Goodwill
Biotechnology	$	119,450		$	95,124		$	84,336
Clinical Controls		56,349			56,349			0
Protein Platforms		214,839			0			0
Consolidated goodwill	$	390,638		$	151,473		$	84,336

Intangible assets, net
Biotechnology	$	68,777		$	53,778		$	40,552
Clinical Controls		49,130			54,998			0
Protein Platforms		174,932			0			0
Consolidated intangible assets, net	$	292,839		$	108,776		$	40,552

Assets
Biotechnology	$	439,377		$	685,302		$	580,085
Clinical Controls		66,101			55,615			24,887
Protein Platforms		444,899			0			0
Segment assets		950,378			740,917			604,972
Corporate cash and available- for- sale investments		52,800			60,142			108,504
Corporate property and equipment		58,270			60,350			61,296
Corporate, other		1,912			1,082			3,326
Consolidated assets	$	1,063,360		$	862,491		$	778,098

Depreciation and amortization
Biotechnology	$	13,820		$	10,879		$	10,781
Clinical Controls		7,963			7,205			389
Protein Platforms		13,364			0			0
Segment depreciation and amortization		35,147			18,084			11,170
Corporate		2,079			1,091			1,151
Consolidated depreciation and amortization	$	37,226		$	19,175		$	12,321

Capital purchases
Biotechnology	$	9,794		$	4,157		$	3,248
Clinical Controls		1,932			5,687			6,914
Protein Platforms		8,179
Segment capital purchases		19,905			9,844			10,162
Corporate		0			3,977			12,292
Consolidated capital purchases	$	19,905		$	13,821		$	22,454

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	Year Ended June 30,
	2015		20 14		20 13
External sales
United States	$	245,217	$	190,359	$	164,308
Europe		134,077		97,157		88,297
China		26,105		18,878		14,106
Other Asia		23,806		32,704		28,608
Rest of world		23,041		18,665		15,256
Total external sales	$	452,246	$	357,763	$	310,575
Long-lived assets
United States and Canada	$	119,075	$	109,790	$	103,541
Europe		11,239		8,340		7,129
China		1,286		678		117
Total long-lived assets	$	131,600	$	118,808	$	110,787